285 related articles for article (PubMed ID: 16107734)
1. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.
Rodrik V; Zheng Y; Harrow F; Chen Y; Foster DA
Mol Cell Biol; 2005 Sep; 25(17):7917-25. PubMed ID: 16107734
[TBL] [Abstract][Full Text] [Related]
2. Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells.
Rodrik V; Gomes E; Hui L; Rockwell P; Foster DA
FEBS Lett; 2006 Oct; 580(24):5647-52. PubMed ID: 16996503
[TBL] [Abstract][Full Text] [Related]
3. Alternative phospholipase D/mTOR survival signal in human breast cancer cells.
Chen Y; Rodrik V; Foster DA
Oncogene; 2005 Jan; 24(4):672-9. PubMed ID: 15580312
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
5. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
Sengupta S; Schiff R; Katzenellenbogen BS
Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
[TBL] [Abstract][Full Text] [Related]
6. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
7. Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase.
Gaben AM; Saucier C; Bedin M; Redeuilh G; Mester J
Mol Endocrinol; 2004 Nov; 18(11):2700-13. PubMed ID: 15297603
[TBL] [Abstract][Full Text] [Related]
8. Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells.
Gaben AM; Sabbah M; Redeuilh G; Bedin M; Mester J
BMC Cancer; 2012 Jul; 12():291. PubMed ID: 22799881
[TBL] [Abstract][Full Text] [Related]
9. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells.
Yue W; Wang J; Li Y; Fan P; Santen RJ
Int J Cancer; 2005 Dec; 117(5):746-54. PubMed ID: 15957161
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells.
Hurd C; Dinda S; Khattree N; Moudgil VK
Oncogene; 1999 Jan; 18(4):1067-72. PubMed ID: 10023683
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-induced post-transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells.
Santos GF; Scott GK; Lee WM; Liu E; Benz C
J Biol Chem; 1988 Jul; 263(20):9565-8. PubMed ID: 3290209
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
[TBL] [Abstract][Full Text] [Related]
13. PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas.
Gozgit JM; Pentecost BT; Marconi SA; Ricketts-Loriaux RS; Otis CN; Arcaro KF
Br J Cancer; 2007 Sep; 97(6):809-17. PubMed ID: 17726467
[TBL] [Abstract][Full Text] [Related]
14. Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid.
Kam Y; Exton JH
FASEB J; 2004 Feb; 18(2):311-9. PubMed ID: 14769825
[TBL] [Abstract][Full Text] [Related]
15. Phospholipase D confers rapamycin resistance in human breast cancer cells.
Chen Y; Zheng Y; Foster DA
Oncogene; 2003 Jun; 22(25):3937-42. PubMed ID: 12813467
[TBL] [Abstract][Full Text] [Related]
16. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
17. Acetaminophen-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-myc RNA expression and NF-kappaB activity.
Gadd SL; Hobbs G; Miller MR
Toxicol Sci; 2002 Apr; 66(2):233-43. PubMed ID: 11896290
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
Yu J; Henske EP
Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601
[TBL] [Abstract][Full Text] [Related]
19. Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells.
Mazumdar A; Kumar R
FEBS Lett; 2003 Jan; 535(1-3):6-10. PubMed ID: 12560069
[TBL] [Abstract][Full Text] [Related]
20. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
